Skip to content

Application of hydromorphone combined with ropivacaine serratus anterior plane block in postoperative analgesia of breast cancer

Application of hydromorphone combined with ropivacaine serratus anterior plane block in postoperative analgesia of breast cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064798
Enrollment
Unknown
Registered
2022-10-18
Start date
2022-10-17
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast postoperative pain

Interventions

The experimental group:10ug/kg hydromorphone injection was added to the block solution
Conrol group:ropivacaine

Sponsors

Chongqing University Fuling Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old who undergo elective breast surgery; 2. ASA level I-III; 3. Sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Infection at the puncture site; 2. diabetes peripheral neuropathy; 3. Chronic pain patients or drug addicts who have been taking opioid drugs for a long time (with pain lasting for more than 3 months and taking opioid drugs>=10mg or oxycodone for more than 3 months); 4. Pregnancy; 5. Research related drug allergies; 6. Individuals with cognitive impairment who are unable to communicate effectively.

Design outcomes

Primary

MeasureTime frame
Postoperative activity NRS score;

Secondary

MeasureTime frame
Intraoperative opioid use;NRS pain score of each time period after that;Postoperative analgesic drug dosage;Incidence of postoperative chronic pain;

Countries

China

Contacts

Public ContactWang Wei

Chongqing University Fuling Hospital

381644818@qq.com+86 15215153008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026